Search Results - "Dutta, Sayanika"

  • Showing 1 - 7 results of 7
Refine Results
  1. 1

    Functional aspects of T cell diversity in visceral leishmaniasis by Jawed, Junaid Jibran, Dutta, Sayanika, Majumdar, Subrata

    Published in Biomedicine & pharmacotherapy (01-09-2019)
    “…Co-ordination between innate and adaptive immunity is a foremost crucial immunological interactions. The interaction is beneficial for the survival of the host…”
    Get full text
    Journal Article
  2. 2

    Abstract 6603: A TBX2-driven signaling switch from androgen receptor to glucocorticoid receptor confers enzalutamide resistance in prostate cancer by Dutta, Sayanika, Patel, Girijesh Kumar, Khedmatgozar, Hamed, Latour, Daniel, Welsh, Jonathan, Tripathi, Manisha, Nandana, Srinivas

    Published in Cancer research (Chicago, Ill.) (22-03-2024)
    “…Background: Recent studies suggest that glucocorticoid receptor (GR) activation can cause enzalutamide resistance in advanced prostate cancer (PCa) via…”
    Get full text
    Journal Article
  3. 3

    Abstract A011: TBX2 acts as a molecular switch to downregulate androgen receptor and upregulate glucocorticoid receptor signaling in castrate resistant prostate cancer by Dutta, Sayanika, Patel, Girijesh, Khedmatgozar, Hamed, Latour, Daniel, Tripathi, Manisha, Nandana, Srinivas

    Published in Cancer research (Chicago, Ill.) (02-06-2023)
    “…Background: A major obstacle in the treatment of metastatic castrate resistant prostate cancer (mCRPC) is acquired resistance to androgen deprivation therapy…”
    Get full text
    Journal Article
  4. 4

    Abstract 1445: TBX2 acts as a molecular switch to downregulate androgen receptor and upregulate glucocorticoid receptor signaling in castrate resistant prostate cancer by Dutta, Sayanika, Patel, Girijesh, Khedmatgozar, Hamed, Latour, Daniel, Tripathi, Manisha, Nandana, Srinivas

    Published in Cancer research (Chicago, Ill.) (04-04-2023)
    “…Background: A major obstacle in the treatment of metastatic castrate resistant prostate cancer (mCRPC) is acquired resistance to androgen deprivation therapy…”
    Get full text
    Journal Article
  5. 5

    Abstract B024: TBX2highmiR-375-3plowRBPJhigh signaling drives prostate cancer bone metastatic phenotype via exosomes by Patel, Girijesh Kumar, Dutta, Sayanika, Khedmatgozar, Hamed, Tripathi, Manisha, Nandana, Srinivas

    Published in Cancer research (Chicago, Ill.) (15-01-2023)
    “…Recent studies have shown that exosome secretion by prostate cancer (PCa) cells fosters multiple facets of PCa progression and metastasis, mediated in…”
    Get full text
    Journal Article
  6. 6

    Abstract 5999: TBX2 promotes prostate cancer bone-metastatic phenotype through exosomal microRNA-375-3p by Patel, Girijesh Kumar, Dutta, Sayanika, Khedmatgozar, Hamed, Tripathi, Manisha, Nandana, Srinivas

    Published in Cancer research (Chicago, Ill.) (15-06-2022)
    “…Introduction: Bone is the preferred site of metastasis in about 80% of advanced prostate cancer (PCa) patients. The molecular mechanisms that drive bone…”
    Get full text
    Journal Article
  7. 7

    TBX2 Drives Neuroendocrine Prostate Cancer through Exosome-Mediated Repression of miR-200c-3p by Patel, Girijesh, Dutta, Sayanika, Mahmud Syed, Mosharaf, Ramachandran, Sabarish, Sharma, Monica, Rajamanickam, Venkatesh, Ganapathy, Vadivel, DeGraff, David, Pruitt, Kevin, Tripathi, Manisha, Nandana, Srinivas

    Published in Cancers (07-10-2021)
    “…Deciphering the mechanisms that drive transdifferentiation to neuroendocrine prostate cancer (NEPC) is crucial to identifying novel therapeutic strategies…”
    Get full text
    Journal Article